VolitionRx Limited (VNRX) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -1352.2%, revenue growth -2.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.73M |
| Revenue (TTM) | $0.0B |
| Net Margin | -1352.2% |
| Return on Equity | 76.4% |
| Operating Margin (TTM) | -790.2% |
| Debt / Equity | -0.21 |
| Current Ratio | 0.30 |
| Net Debt / EBITDA | -0.2 |
| Interest Coverage | -26.3 |
| Revenue Growth (YoY) | -2.0% |
| FCF Growth (YoY) | 64.9% |
| Price / Sales | 1.28 |
| FCF Yield | -621.3% |
| Altman Z-Score | -63.17 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
VNRX overview · VNRX earnings · VNRX KPIs · VNRX documents · VNRX ownership · VNRX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.